fashion -WSS

fashion

author：comprehensive 2025-09-06 04:27:28 - browse：593

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Gritstone Bio's cancer vaccine test, and more on Novartis' deal

explore

Wikipedia

WSS

The Biogen Aduhelm mess could happen again

Medicare Advantage plans can’t deny care with AI, CMS warns

Case highlights the risks of experimental stem cell therapy

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Big Tobacco's 'harm reduction': Is it for real, or a sham?

hotspot

fashion

leisure time

Alkermes shareholders re

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Jerome Adams on the need for new antivirals for Covid

Solving academic medical centers' existential crisis

Hollywood unions extend contract negotiations for actors

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Guidelines to prevent youth baseball injuries need more muscle

Addiction experts warn against a second 'war on drugs'

Medicare proposal to cover medical devices draws a mixed reaction

The CDC's new social media misinformation war

explore

What’s missing from the debate over nursing home staff minimums

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

A single Democrat is willing to weaken Medicare negotiation power

A single Democrat is willing to weaken Medicare negotiation power

Cano Health’s bankruptcy is a warning for Medicare Advantage

explore

Wikipedia

hotspot

hotspot